Fever, shock, and pancytopenia in a patient treated with alemtuzumab.
Bauer
Martijn P
MP
Departments of 1Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
van Burgel
Nathalie D
ND
Marijt
W A Erik
WA
van Dissel
Jaap T
JT
von dem Borne
Peter A
PA
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D005334:Fever / Q000209:etiology; D006801:Humans; D051359:Lymphohistiocytosis, Hemophagocytic / Q000139:chemically induced* / Q000175:diagnosis* / Q000473:pathology / Q000503:physiopathology; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D010198:Pancytopenia / Q000209:etiology; D012769:Shock / Q000209:etiology; D014376:Tuberculosis / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab